AUPH logo

Aurinia Pharmaceuticals (AUPH) Company Overview

Profile

Full Name:

Aurinia Pharmaceuticals Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

September 3, 2014

Indexes:

Not included

Description:

Aurinia Pharmaceuticals (AUPH) is a biopharmaceutical company focused on developing and commercializing innovative therapies for kidney diseases. Their main product, LUPKYNIS, treats lupus nephritis, a serious kidney condition. Aurinia aims to improve patient outcomes through advanced research and targeted treatments.

Key Details

Price

$8.05

Annual Revenue

$235.13 M(+33.97% YoY)

Annual EPS

$0.04(+107.41% YoY)

PE Ratio

161.00

Beta

0.67

Events Calendar

Earnings

Next earnings date:

May 2, 2025

Recent quarterly earnings:

Feb 27, 2025

Recent annual earnings:

Feb 27, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Oct 23, 2013

Analyst ratings

Recent major analysts updates

Sep 16, 24 Cantor Fitzgerald
Overweight
Sep 9, 24 Cantor Fitzgerald
Overweight
Sep 6, 24 HC Wainwright & Co.
Buy
Mar 1, 24 HC Wainwright & Co.
Buy
Feb 23, 24 Cantor Fitzgerald
Overweight
Feb 22, 24 HC Wainwright & Co.
Buy
Feb 16, 24 RBC Capital
Outperform
Sep 22, 23 HC Wainwright & Co.
Buy
Aug 7, 23 HC Wainwright& Co.
Buy
Aug 7, 23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Aurinia Pharmaceuticals?
  • Does Aurinia Pharmaceuticals pay dividends?
  • What sector is Aurinia Pharmaceuticals in?
  • What industry is Aurinia Pharmaceuticals in?
  • What country is Aurinia Pharmaceuticals based in?
  • When did Aurinia Pharmaceuticals go public?
  • Is Aurinia Pharmaceuticals in the S&P 500?
  • Is Aurinia Pharmaceuticals in the NASDAQ 100?
  • Is Aurinia Pharmaceuticals in the Dow Jones?
  • When was Aurinia Pharmaceuticals's last earnings report?
  • When does Aurinia Pharmaceuticals report earnings?
  • Should I buy Aurinia Pharmaceuticals stock now?

What is the ticker symbol for Aurinia Pharmaceuticals?

The ticker symbol for Aurinia Pharmaceuticals is NASDAQ:AUPH

Does Aurinia Pharmaceuticals pay dividends?

No, Aurinia Pharmaceuticals does not pay dividends

What sector is Aurinia Pharmaceuticals in?

Aurinia Pharmaceuticals is in the Healthcare sector

What industry is Aurinia Pharmaceuticals in?

Aurinia Pharmaceuticals is in the Biotechnology industry

What country is Aurinia Pharmaceuticals based in?

Aurinia Pharmaceuticals is headquartered in Canada

When did Aurinia Pharmaceuticals go public?

Aurinia Pharmaceuticals's initial public offering (IPO) was on September 3, 2014

Is Aurinia Pharmaceuticals in the S&P 500?

No, Aurinia Pharmaceuticals is not included in the S&P 500 index

Is Aurinia Pharmaceuticals in the NASDAQ 100?

No, Aurinia Pharmaceuticals is not included in the NASDAQ 100 index

Is Aurinia Pharmaceuticals in the Dow Jones?

No, Aurinia Pharmaceuticals is not included in the Dow Jones index

When was Aurinia Pharmaceuticals's last earnings report?

Aurinia Pharmaceuticals's most recent earnings report was on Feb 27, 2025

When does Aurinia Pharmaceuticals report earnings?

The next expected earnings date for Aurinia Pharmaceuticals is May 2, 2025

Should I buy Aurinia Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions